

# Genzyme Corporation (GENZ)

## Analyst Schedule

(Unaudited, amounts in thousands, except percentage amounts)

	Q1-08	Q2-08	Q3-08	Q4-08	Q1-09	Q1-09 vs. Q1-08 % B/(W)	FY 2007	FY 2008	YTD 03/31/09
<b>Total revenues:</b>									
<b>Genetic Diseases</b>									
Cerezyme	\$ 304,303	\$ 319,360	\$ 309,280	\$ 306,034	\$ 295,970	(3%)	\$ 1,133,153	\$ 1,238,977	\$ 295,970
Fabrazyme	116,475	126,608	125,619	125,558	122,201	5%	424,284	494,260	122,201
Myozyme	67,324	77,222	76,663	74,967	67,392	0%	200,728	296,176	67,392
Aldurazyme	37,015	38,834	38,236	37,579	36,837		-	151,664	36,837
Other Genetic Diseases	9,772	10,437	11,367	14,039	14,650	50%	8,314	45,615	14,650
Total Genetic Diseases product and service revenue	534,889	572,461	561,165	558,177	537,050	0%	1,766,479	2,226,692	537,050
R&D Revenue	-	-	-	-	-		1,059	-	-
<b>Total Genetic Diseases</b>	<b>534,889</b>	<b>572,461</b>	<b>561,165</b>	<b>558,177</b>	<b>537,050</b>	0%	<b>1,767,538</b>	<b>2,226,692</b>	<b>537,050</b>
<b>Cardiomatabolic and Renal</b>									
Renagel and Renvela (including Sevelamer)	168,694	168,567	170,992	169,476	170,599	1%	602,670	677,729	170,599
Hectorol	29,076	30,852	33,825	34,400	33,030	14%	115,708	128,153	33,030
Subtotal	197,770	199,419	204,817	203,876	203,629	3%	718,378	805,882	203,629
Thyrogen	33,785	39,448	38,153	37,062	38,826	15%	113,587	148,448	38,826
Other Cardiomatabolic and Renal	251	333	573	496	494	97%	103	1,653	494
Total Cardiomatabolic and Renal product and service revenue	231,806	239,200	243,543	241,434	242,949	5%	832,068	955,983	242,949
R&D revenue	32	85	56	27	13	(59%)	1,200	200	13
<b>Total Cardiomatabolic and Renal</b>	<b>231,838</b>	<b>239,285</b>	<b>243,599</b>	<b>241,461</b>	<b>242,962</b>	5%	<b>833,268</b>	<b>956,183</b>	<b>242,962</b>
<b>Biosurgery</b>									
Synvisc	56,142	70,927	67,513	68,512	63,171	13%	242,319	263,094	63,171
Sepra products	30,604	34,780	33,001	35,278	34,304	12%	104,318	133,663	34,304
Other Biosurgery	24,313	24,690	21,787	20,908	21,485	(12%)	74,673	91,698	21,485
Total Biosurgery product and service revenue	111,059	130,397	122,301	124,698	118,960	7%	421,310	488,455	118,960
R&D revenue	603	818	661	563	562	(7%)	5,337	2,645	562
<b>Total Biosurgery</b>	<b>111,662</b>	<b>131,215</b>	<b>122,962</b>	<b>125,261</b>	<b>119,522</b>	7%	<b>426,647</b>	<b>491,100</b>	<b>119,522</b>
<b>Hematologic Oncology</b>									
Total Hematologic Oncology product and service revenue	22,691	26,443	26,328	27,437	34,423	52%	69,927	102,899	34,423
R&D revenue	1,189	1,903	2,292	9,055	1,484	25%	7,006	14,439	1,484
<b>Total Hematologic Oncology</b>	<b>23,880</b>	<b>28,346</b>	<b>28,620</b>	<b>36,492</b>	<b>35,907</b>	50%	<b>76,933</b>	<b>117,338</b>	<b>35,907</b>
<b>Other</b>									
Genetic/Diagnostics product and service revenue	114,748	116,863	121,163	124,840	129,194	13%	410,917	477,614	129,194
Transplant product and service revenue	45,930	47,763	47,784	50,723	52,666	15%	174,826	192,200	52,666
Other product and service revenue	31,009	29,296	28,598	30,252	23,501	(24%)	108,577	119,155	23,501
Total Other product and service revenue	191,687	193,922	197,545	205,815	205,361	7%	694,320	788,969	205,361
R&D revenue	6,105	5,905	6,393	6,354	8,069	32%	14,813	24,757	8,069
<b>Total Other</b>	<b>197,792</b>	<b>199,827</b>	<b>203,938</b>	<b>212,169</b>	<b>213,430</b>	8%	<b>709,133</b>	<b>813,726</b>	<b>213,430</b>
<b>Total revenues</b>	<b>\$ 1,100,061</b>	<b>\$ 1,171,134</b>	<b>\$ 1,160,284</b>	<b>\$ 1,173,560</b>	<b>\$ 1,148,871</b>	4%	<b>\$ 3,813,519</b>	<b>\$ 4,605,039</b>	<b>\$ 1,148,871</b>

All amounts herein are presented in accordance with GAAP and are provided for quantitative analysis only and should be read in conjunction with the text of the Earnings Release and our audited financial statements filed with the Securities and Exchange Commission. Please refer to our Form 10-Q's and Form 10-K's for an in-depth discussion and analysis of our results of operations and financial position and for detailed information regarding specific material transactions in a particular period.